AUTHOR=Mutlu Yasa Gul , Yıgıt Kaya Sureyya , Maral Senem , Melek Elif , Baslar Zafer , Kaynar Leylagul , Sevindik Omur Gokmen 

TITLE=Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

JOURNAL=Frontiers in Immunology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1276295

DOI=10.3389/fimmu.2023.1276295

ISSN=1664-3224

ABSTRACT=<p>Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear. Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM. However, its efficacy in treating CNS-MM has not been reported. We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.</p>